6617.TWO Gongwin Biopharm Holdings Co. Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
76.00 TWD
Close of Nov 5, 2026
58.30 149.00
Market cap
TWD 9.21B
P/E
-
P/B
5.57x
ROE
-7.0%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6617.TWO undervalued?

Graham number

The Graham number of Gongwin Biopharm Holdings Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Gongwin Biopharm Holdings Co. Ltd. fundamental analysis

No fundamental analysis for Gongwin Biopharm Holdings Co. Ltd. yet.

Gongwin Biopharm Holdings Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Gongwin Biopharm Holdings Co. Ltd.

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore. It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural…

Full company profile